Generation, evolution, interfering factors, applications, and challenges of patient-derived xenograft models in immunodeficient mice
Abstract Establishing appropriate preclinical models is essential for cancer research. Evidence suggests that cancer is a highly heterogeneous disease. This follows the growing use of cancer models in cancer research to avoid these differences between xenograft tumor models and patient tumors. In re...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-06-01
|
| Series: | Cancer Cell International |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12935-023-02953-3 |
| _version_ | 1797795429106057216 |
|---|---|
| author | Mingtang Zeng Zijing Ruan Jiaxi Tang Maozhu Liu Chengji Hu Ping Fan Xinhua Dai |
| author_facet | Mingtang Zeng Zijing Ruan Jiaxi Tang Maozhu Liu Chengji Hu Ping Fan Xinhua Dai |
| author_sort | Mingtang Zeng |
| collection | DOAJ |
| description | Abstract Establishing appropriate preclinical models is essential for cancer research. Evidence suggests that cancer is a highly heterogeneous disease. This follows the growing use of cancer models in cancer research to avoid these differences between xenograft tumor models and patient tumors. In recent years, a patient-derived xenograft (PDX) tumor model has been actively generated and applied, which preserves both cell–cell interactions and the microenvironment of tumors by directly transplanting cancer tissue from tumors into immunodeficient mice. In addition to this, the advent of alternative hosts, such as zebrafish hosts, or in vitro models (organoids and microfluidics), has also facilitated the advancement of cancer research. However, they still have a long way to go before they become reliable models. The development of immunodeficient mice has enabled PDX to become more mature and radiate new vitality. As one of the most reliable and standard preclinical models, the PDX model in immunodeficient mice (PDX-IM) exerts important effects in drug screening, biomarker development, personalized medicine, co-clinical trials, and immunotherapy. Here, we focus on the development procedures and application of PDX-IM in detail, summarize the implications that the evolution of immunodeficient mice has brought to PDX-IM, and cover the key issues in developing PDX-IM in preclinical studies. |
| first_indexed | 2024-03-13T03:18:48Z |
| format | Article |
| id | doaj.art-145046369ad1486b869b21277a6c3d2a |
| institution | Directory Open Access Journal |
| issn | 1475-2867 |
| language | English |
| last_indexed | 2024-03-13T03:18:48Z |
| publishDate | 2023-06-01 |
| publisher | BMC |
| record_format | Article |
| series | Cancer Cell International |
| spelling | doaj.art-145046369ad1486b869b21277a6c3d2a2023-06-25T11:29:53ZengBMCCancer Cell International1475-28672023-06-0123112310.1186/s12935-023-02953-3Generation, evolution, interfering factors, applications, and challenges of patient-derived xenograft models in immunodeficient miceMingtang Zeng0Zijing Ruan1Jiaxi Tang2Maozhu Liu3Chengji Hu4Ping Fan5Xinhua Dai6Department of Pharmacy, West China Hospital, Sichuan UniversityDepartment of Pharmacy, West China Hospital, Sichuan UniversityDepartment of Pharmacy, West China Hospital, Sichuan UniversityDepartment of Pharmacy, West China Hospital, Sichuan UniversityDepartment of Pharmacy, West China Hospital, Sichuan UniversityDepartment of Pharmacy, West China Hospital, Sichuan UniversityDepartment of Laboratory Medicine, West China Hospital, Sichuan UniversityAbstract Establishing appropriate preclinical models is essential for cancer research. Evidence suggests that cancer is a highly heterogeneous disease. This follows the growing use of cancer models in cancer research to avoid these differences between xenograft tumor models and patient tumors. In recent years, a patient-derived xenograft (PDX) tumor model has been actively generated and applied, which preserves both cell–cell interactions and the microenvironment of tumors by directly transplanting cancer tissue from tumors into immunodeficient mice. In addition to this, the advent of alternative hosts, such as zebrafish hosts, or in vitro models (organoids and microfluidics), has also facilitated the advancement of cancer research. However, they still have a long way to go before they become reliable models. The development of immunodeficient mice has enabled PDX to become more mature and radiate new vitality. As one of the most reliable and standard preclinical models, the PDX model in immunodeficient mice (PDX-IM) exerts important effects in drug screening, biomarker development, personalized medicine, co-clinical trials, and immunotherapy. Here, we focus on the development procedures and application of PDX-IM in detail, summarize the implications that the evolution of immunodeficient mice has brought to PDX-IM, and cover the key issues in developing PDX-IM in preclinical studies.https://doi.org/10.1186/s12935-023-02953-3Patient-derived xenograftPreclinical modelCancer researchImmunotherapyImmunodeficiency miceHumanized mice |
| spellingShingle | Mingtang Zeng Zijing Ruan Jiaxi Tang Maozhu Liu Chengji Hu Ping Fan Xinhua Dai Generation, evolution, interfering factors, applications, and challenges of patient-derived xenograft models in immunodeficient mice Cancer Cell International Patient-derived xenograft Preclinical model Cancer research Immunotherapy Immunodeficiency mice Humanized mice |
| title | Generation, evolution, interfering factors, applications, and challenges of patient-derived xenograft models in immunodeficient mice |
| title_full | Generation, evolution, interfering factors, applications, and challenges of patient-derived xenograft models in immunodeficient mice |
| title_fullStr | Generation, evolution, interfering factors, applications, and challenges of patient-derived xenograft models in immunodeficient mice |
| title_full_unstemmed | Generation, evolution, interfering factors, applications, and challenges of patient-derived xenograft models in immunodeficient mice |
| title_short | Generation, evolution, interfering factors, applications, and challenges of patient-derived xenograft models in immunodeficient mice |
| title_sort | generation evolution interfering factors applications and challenges of patient derived xenograft models in immunodeficient mice |
| topic | Patient-derived xenograft Preclinical model Cancer research Immunotherapy Immunodeficiency mice Humanized mice |
| url | https://doi.org/10.1186/s12935-023-02953-3 |
| work_keys_str_mv | AT mingtangzeng generationevolutioninterferingfactorsapplicationsandchallengesofpatientderivedxenograftmodelsinimmunodeficientmice AT zijingruan generationevolutioninterferingfactorsapplicationsandchallengesofpatientderivedxenograftmodelsinimmunodeficientmice AT jiaxitang generationevolutioninterferingfactorsapplicationsandchallengesofpatientderivedxenograftmodelsinimmunodeficientmice AT maozhuliu generationevolutioninterferingfactorsapplicationsandchallengesofpatientderivedxenograftmodelsinimmunodeficientmice AT chengjihu generationevolutioninterferingfactorsapplicationsandchallengesofpatientderivedxenograftmodelsinimmunodeficientmice AT pingfan generationevolutioninterferingfactorsapplicationsandchallengesofpatientderivedxenograftmodelsinimmunodeficientmice AT xinhuadai generationevolutioninterferingfactorsapplicationsandchallengesofpatientderivedxenograftmodelsinimmunodeficientmice |